Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
TAO (troleandomycin) is an oral macrolide antibiotic suspension developed by Pfizer currently in pre-launch stage. The drug's specific indications have not been disclosed in available data. Troleandomycin is a small-molecule macrolide with broad-spectrum antimicrobial activity.
Pre-launch stage indicates active commercial planning and team buildout, with significant opportunity for early-stage brand positioning and launch strategy work.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
ROTAO 1 - Feasibility and Safety of the TAVIPILOT Tele-operated Robot During Transcatheter Aortic Valve Replacement (TAVR/TAVI)
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
TAO Outpatient Trial for Anxiety and Depression
TruFreeze™ Airway Obstruction: TAO STUDY
Worked on TAO at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
TAO is in pre-launch phase with no currently linked job openings, but this stage typically signals upcoming hiring waves for brand teams, sales forces, and medical affairs. Joining a pre-launch team offers exposure to launch strategy, market positioning, and team building in a greenfield environment.